Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

33.41 +0.04 (+0.12%)
Streaming Delayed Price Updated: 3:44 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
News headline image
1 Cash-Producing Stock to Own for Decades and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
5 Hot Stocks With Summer Buybacks You Can Cash In On ↗
The five stocks on this list issued aggressive buyback authorizations in June or July and have the power to follow through with their plans. 
Via MarketBeat
News headline image
1 Safe-and-Steady Stock to Keep an Eye On and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Collegium Announces $150 Million Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your Radar
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks Facing Headwinds
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company... 
Via StockStory
News headline image
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after market close. Here’s what to look for. 
Via StockStory
News headline image
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
News headline image
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
2 Reasons to Watch COLL and 1 to Stay Cautious
Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next... 
Via StockStory
News headline image
What Analysts Are Saying About Collegium Pharmaceutical Stock ↗
 
Via Benzinga
News headline image
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical ↗
 
Via Benzinga
News headline image
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.